Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | FASN | P49327 | 8/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906430 | 0.95 | KCNH2 (0.46) | KCNH2HRH3MAOAMAOBFASN | |
| SCHEMBL28935583 | 0.90 | MAOA (0.39) | KCNH2MAOAMAOBCYP19A1CYP11B1 | |
| SCHEMBL19662088 | 0.84 | KCNH2 (0.50) | KCNH2HRH3 | |
| SCHEMBL4699085 | 0.80 | DRD2 (0.51) | POLBCYP19A1 | |
| SCHEMBL13818581 | 0.79 | KCNH2 (0.43) | KCNH2HRH3FASN | |
| SCHEMBL13818537 | 0.79 | KCNH2 (0.43) | KCNH2HRH3FASN | |
| SCHEMBL1226208 | 0.78 | TSHR (0.50) | MAOAMAOBCYP19A1 | |
| SCHEMBL1225840 | 0.78 | TSHR (0.50) | MAOAMAOBCYP19A1 | |
| SCHEMBL1225841 | 0.78 | TSHR (0.50) | MAOAMAOBCYP19A1 | |
| SCHEMBL1779534 | 0.77 | CYP11B1 (0.41) | KCNH2MAOAMAOBCYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | CORTICAL PTY LTD (AU) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | MIF, CCL2, CCL11 | KCNH2 4804/4885HRH3 1206/4885MAOA 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.